Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Cavion logo — Empowering therapies for cancer and neurologic diseases thro...

Cavion

Empowering therapies for cancer and neurologic diseases through pioneering ion channel inhibition

Founded 2003 Series A Total: $31.10M Biotechnology, Health Care +1

General Information

Company Name Cavion
Founded Year 2003
Founders / Decision Makers
Team member
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Series A
Social

BounceWatch is an independent company data service, not affiliated with Cavion. To contact Cavion, visit cavionpharma.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Cavion compare?

A PDF of Cavion and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Cavion soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Cavion

Cavion, a clinical-stage pharmaceutical company, focuses on developing treatments for cancer and neurological disorders by selectively inhibiting the T-type calcium channel (Cav3). Founded in 2003, it has made strides in pioneering therapies that engage Cav3 for solid tumor treatment. The company is currently undergoing Phase 1 safety and dose-finding clinical trials for brain cancer, with the goal of enhancing the effectiveness of combined chemotherapy, radiation, and targeted therapies for all solid tumors. Cavion's neurology program aims to introduce non-addictive, non-opioid T-type calcium channel antagonists for patients suffering from neuropathic pain and is also developing therapies for other neurological diseases like essential tremor, Parkinson’s disease, epilepsy, and Angelman syndrome. The company's last investment was a $26.10M Series A investment at 06 January 2017, with participation from Novartis Venture Fund, Lilly Ventures, and Enso Ventures. Cavion's focus on pioneering ion channel inhibition for cancer and neurological diseases, along with its promising preclinical studies and ongoing clinical trials, positions it as a potential disruptor in the biotechnology, healthcare, and pharmaceutical industries.

Business keywords: pharmaceutical company, clinical-stage, ion channel inhibition, solid tumor treatment, neurological disorders, T-type calcium channel, drug development, cancer therapy, neurology treatment, Phase 1 clinical trials, neuropathic pain, chemotherapy, radiation therapy, targeted therapies, neurologic diseases

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series A $26.10M 3
Novartis Venture Fund Lilly Ventures Enso Ventures
Novartis Venture Fund, Lilly Ventures +1
06 Jan 2017
Debt Financing $5.00M -
10 Nov 2015
Seed Round Undisclosed 1
Virginia Venture Partners
22 Dec 2005

Cavion Alternatives & Competitors

View All Alternatives
Cavion vs
Lisata Therapeutics, Inc.
Lisata Therapeutics, Inc. United States

Targeted Therapy Delivered

Acquired
39 employees
Biotechnology, Health and Wellness
Cavion vs
Cleveland Biolabs
Cleveland Biolabs United States

Cleveland BioLabs, Inc. (Nasdaq:CBLI) is a clinical-stage biotechnology company with a focus on onco...

Post-IPO Equity
21 employees
Biotechnology, Health Care
Cavion vs
Algiax Pharmaceuticals
Algiax Pharmaceuticals Germany

Disarming chronic neuropathic pain

5 employees
Biotechnology, Health Care
View all alternatives

FAQ About Cavion

Empowering therapies for cancer and neurologic diseases through pioneering ion channel inhibition
Cavion was founded in 2003.
Cavion operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on pharmaceutical company, clinical-stage, ion channel inhibition and solid tumor treatment.
Cavion has completed 3 funding rounds, raising a total of $31.10M. The latest funding stage is Series A.
Top alternatives and competitors to Cavion include Lisata Therapeutics, Inc., Cleveland Biolabs, Algiax Pharmaceuticals, Prescient Therapeutics, NeuroTherapia, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Cavion and Lisata Therapeutics, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Cavion, https://bouncewatch.com/company/cavion, updated 26 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes